CTOs on the Move

Charles River Laboratories

www.criver.com

 
At Charles River, we are passionate about our role in improving the quality of people`s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.criver.com
  • 251 Ballardvale Street
    Wilmington, MA USA 01887
  • Phone: 781.222.6000

Executives

Name Title Contact Details
Arthur Hubbs
Corporate Senior Vice President of Information Technology and Chief Information Officer Profile
Chris Kaczkowski
Sr. Director, Information Security Engineering, Architecture, Threat Intel, and Security Awareness Profile
Matt Dwyer
Director of Information Technology, Sites and Services Profile

Funding

Charles River Laboratories raised $1B on 03/23/2021

Similar Companies

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Neoleukin

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

Ensoma

At Ensoma, we believe every person, no matter where they are in the world, should have access to innovative technologies that are changing the way we treat disease.

VIRxSYS Corporation

VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Armune

Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.